Screener / SEC EDGAR /CIK 0001159036 /10-K filed Feb 17, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Biotechnology

Halozyme Therapeutics, Inc. HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. 10-K, Item 1

Headquarters
San Diego, CA
CEO
Helen Torley
Next results
around Jan 27, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $1.4B through the costs to a net profit of $316.9M · income statement of the 10-K

34% operating margin
Revenue to Gross profit: $1.2BRevenue to Cost of revenue: $228.8MGross profit to Operating profit: $469.0MGross profit to Operating expenses: $698.8MOperating profit to Net profit: $316.9MOperating profit to Tax & other: $152.1MOperating expenses to R&D: $81.5MOperating expenses to Sales, admin & other: $617.3M Revenue: $1.4B REVENUE $1.4B +38% Y/Y Gross profit: $1.2B · 84% margin GROSS PROFIT $1.2B 84% margin Cost of revenue: $228.8M · 16% of revenue COST OF REVENUE $228.8M 16% of revenue Operating profit: $469.0M · 34% margin OPERATING PROFIT $469.0M 34% margin · −15% Y/Y Operating expenses: $698.8M · 50% of revenue OPERATING EXPENSES $698.8M 50% of revenue Net profit: $316.9M · 23% margin NET PROFIT $316.9M 23% margin · −29% Y/Y Tax & other: $152.1M · 11% of revenue TAX & OTHER $152.1M 11% of revenue R&D: $81.5M · 6% of revenue R&D $81.5M 6% of revenue Sales, admin & other: $617.3M · 44% of revenue SALES, ADMIN & OTHER $617.3M 44% of revenue
Gross profit $1.2B 84% margin
Operating profit $469.0M 34% margin · −15% Y/Y
Net profit $316.9M 23% margin · −29% Y/Y
The full income statement, year by year

HALO among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 37.6%, above 87% of 154 peers (their median 10.4%) REVENUE GROWTH 37.6% · above 87% Gross margin: 82.3%, above 84% of 107 peers (their median 63.4%) GROSS MARGIN 82.3% · above 84% Operating margin: 37.4%, above 96% of 138 peers (their median 9.8%) OPERATING MARGIN 37.4% · above 96% Net margin: 26.9%, above 92% of 153 peers (their median 6.7%) NET MARGIN 26.9% · above 92% FCF margin: 49.1%, above 99% of 144 peers (their median 9.9%) FCF MARGIN 49.1% · above 99%
HALO Peer median Below the median

What changed

8 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 17, 2026 against Feb 18, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 9 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +47.9% ($288.2M to $426.3M) vs revenue +37.6% ($1.0B to $1.4B), +10.4 pts apart
  • Critical audit matters changed
    New this year: Valuation of the customer relationship intangible assets acquired in connection with the Elektrofi, Inc. acquisition (“As disclosed in Note 3 of the consolidated financial statements, the Company completed the acquisition of Elektrofi, Inc. (“Elektrofi”) on November 18, 2025, for total consideration of $810.4 million. The acquisition was accounted for as a business combination. The Company recorded intangible assets”). No longer listed: Table of Contents. Same as last year: Determination of Overall Transaction Price for Collaboration Agreements
  • Cash from operations $651.6M vs net income $316.9M (FY ending Dec 31, 2025)
8 more checks with nothing to note
  • Inventory +24.4% ($141.9M to $176.5M) vs revenue +37.6% ($1.0B to $1.4B), -13.2 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

8 paragraphs in Risk Factors that were not in the 10-K filed Feb 18, 2025. Quoted as filed.

All 8 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
    Workforce reduction at federal agencies and changes in U.S. trade policy, including tariffs and potential countermeasures by trading partners, could delay regulatory approval and increase our or our partners’ costs, disrupt global supply chains and have a material adverse impact on our business, financial condition, and results of…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
    We may be required to initiate or defend against legal proceedings related to our intellectual property rights which may be time-consuming and result in substantial litigation expense. For example, in April 2025 we filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. (“Merck”) in the U.S. District Court in New Jersey…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
    Additionally, artificial intelligence (“AI”) based software is increasingly being used in the biopharmaceutical industry including by companies with which we compete. We are increasing the use of AI tools and technology and intend to integrate AI more broadly in our operations with the goal of increasing operational efficiencies,…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$660.1M$829.3M$1.0B$1.4B
Net income$202.1M$281.6M$444.1M$316.9M
Operating cash flow$240.1M$388.6M$479.1M$651.6M
Free cash flow$235.3M$373.3M$468.4M$644.6M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$1.4B ▲ 37.6% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

Halozyme Therapeutics, Inc., San Diego, CA · from the 10-K filed Feb 17, 2026

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners’ proprietary compounds.

Headquarters
San Diego, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 5, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 17, 2026 (open at SEC), compared with the 10-K filed Feb 18, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HALO/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.